言語を選択

NKG2A

NKG2A 詳細

英語名	NK cell lectin-like receptor subfamily C member 1	市販薬剤の数	0
治験薬の数	6	ターゲットの別称	CD159a，NKG2A，KLRC1，Killer Cell Lectin Like Receptor C1，Killer Cell Lectin-Like Receptor Subfamily C， Member 1，CD159 Antigen-Like Family Member A，NKG2-1/B Activating NK Receptor，NKG2-A/B-Activating NK Receptor，NK Cell Receptor A，NKG2-A/NKG2-B Type II Integral Membrane Protein，NKG2-A/B Type II Integral Membrane Protein，Natural Killer Group Protein 2，Natural Killer Cell Lectin，C-Lectin Type II Protein，CD159a Antigen，NKG2，NKG2-B，NKG2-A
研究＆開発段階	Phase 3 Clinical

英語名	NK cell lectin-like receptor subfamily C member 1
ターゲットの別称	CD159a，NKG2A，KLRC1，Killer Cell Lectin Like Receptor C1，Killer Cell Lectin-Like Receptor Subfamily C， Member 1，CD159 Antigen-Like Family Member A，NKG2-1/B Activating NK Receptor，NKG2-A/B-Activating NK Receptor，NK Cell Receptor A，NKG2-A/NKG2-B Type II Integral Membrane Protein，NKG2-A/B Type II Integral Membrane Protein，Natural Killer Group Protein 2，Natural Killer Cell Lectin，C-Lectin Type II Protein，CD159a Antigen，NKG2，NKG2-B，NKG2-A
市販薬剤の数	0
治験薬の数	6
研究＆開発段階	Phase 3 Clinical

NKG2A 製品リスト

属性
Protein (4)
製品ライブラリ
オンライン (4)
種
Human (2)Cynomolgus (1)Mouse (1)
タグ
His Tag (3)Fc Tag (1)
マーカー
Unconjugated (4)

製品番号	種	発現システム	製品説明
HOT NKA-H5244	Human	HEK293	Human NKG2A / CD159a Protein, His Tag
HOT NKA-M52H5	Mouse	HEK293	Mouse NKG2A / CD159a Protein, His Tag
HOT NKA-C5245	Cynomolgus	HEK293	Cynomolgus NKG2A / CD159a Protein, His Tag
NKA-H526c	Human	HEK293	Human NKG2A / CD159a Protein, Fc Tag

総数量4

NKG2Aバックグランド

NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation, also known as KLRC1, CD159a, NK cell receptor A and NKG2-A/NKG2-B type II integral membrane protein. NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. NKG2A blockade therapy operated through CD8 T cells, but not NK cells. The increase in NKG2A expression might be induced by IL-10, which was present at a high level in the plasma of HCC patients. Blocking IL-10 could specifically inhibit NKG2A expression in NK cells. These findings indicate that NKG2A expression is influenced by factors from cancer nests and contributes to NK cell exhaustion, suggesting that NKG2A blockade has the potential to restore immunity against liver tumors by reversing NK cell exhaustion.

NKG2A分子の別称

NKG2A,CD159a,KLRC1,NK cell receptor A

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Monalizumab	NNC-0141-0000-0100; NNC 0141-0000-0100; IPH-22XX; IPH-22; NN-8765; IPH-2201	Phase 3 Clinical	Novo Nordisk A/S	Arthritis, Rheumatoid; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Genital Neoplasms, Female; Head and Neck Neoplasms; Hematologic Neoplasms; Inflammation; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Oral Squamous Cell Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms	詳細
BMS-986315	BMS-986315	Phase 2 Clinical	Bristol-Myers Squibb Company	Carcinoma, Non-Small-Cell Lung; Solid tumours	詳細
S-095029	S-095029	Phase 2 Clinical	Institut De Recherches Internationales Servier	Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Solid tumours; Stomach Neoplasms	詳細
HY000102	HY-0102; HY-000102	Phase 2 Clinical	Shanghai HyaMab Biotech Co Ltd	Pancreatic Neoplasms; Solid tumours	詳細
XB-628	XB628	Phase 1 Clinical	Exelixis Inc	Neoplasms; Solid tumours	詳細
BRY-805	BRY805; BRY-805	Phase 1 Clinical	Hisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co Ltd	Solid tumours	詳細

レビュー

A***n2024-09-17
0評価
Human NKG2A / CD159a Protein, His Tag
I used this recombinant protein to test function of a gRV transduction on iPS-derived cells. The product went into solution quickly during reconstitution and provided expected results from positive controls and testing samples. Signal was clear on a flow cytometry based readout using Streptavidin-Brilliant Violet 711. I used this at 5 ug at a concentration of 100 ug/mL on 50,000 total cells. No support was needed, as the provided data sheet and CoA are thorough and easy to follow. Very satisfied with my experience.